Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021

SELL
$34.54 - $47.25 $420,489 - $575,221
-12,174 Closed
0 $0
Q1 2021

May 07, 2021

SELL
$42.51 - $63.78 $200,689 - $301,105
-4,721 Reduced 27.94%
12,174 $547,000
Q4 2020

Feb 10, 2021

BUY
$45.3 - $60.27 $35,560 - $47,311
785 Added 4.87%
16,895 $955,000
Q3 2020

Oct 28, 2020

SELL
$47.45 - $62.95 $25,148 - $33,363
-530 Reduced 3.19%
16,110 $764,000
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $81,987 - $106,837
-1,750 Reduced 9.52%
16,640 $981,000
Q1 2020

May 13, 2020

SELL
$41.6 - $63.4 $91,520 - $139,480
-2,200 Reduced 10.68%
18,390 $869,000
Q3 2019

Nov 08, 2019

SELL
$59.06 - $72.15 $89,771 - $109,668
-1,520 Reduced 6.87%
20,590 $1.23 Million
Q2 2019

Aug 06, 2019

BUY
$62.09 - $86.14 $9,313 - $12,921
150 Added 0.68%
22,110 $1.42 Million
Q1 2019

May 10, 2019

BUY
$52.92 - $81.17 $179,928 - $275,978
3,400 Added 18.32%
21,960 $1.78 Million
Q4 2018

Feb 14, 2019

BUY
$43.37 - $59.54 $455,385 - $625,170
10,500 Added 130.27%
18,560 $1 Million
Q3 2018

Nov 26, 2018

SELL
$42.88 - $53.7 $215,900 - $270,379
-5,035 Reduced 38.45%
8,060 $416,000
Q2 2018

Aug 09, 2018

SELL
$40.53 - $50.7 $25,331 - $31,687
-625 Reduced 4.56%
13,095 $546,000
Q1 2018

Jul 26, 2018

BUY
$44.08 - $55.05 $578,109 - $721,980
13,115 Added 2167.77%
13,720 $605,000
Q1 2018

May 03, 2018

SELL
$44.08 - $55.05 $588,027 - $734,367
-13,340 Reduced 95.66%
605 $13.7 Million
Q4 2017

Feb 06, 2018

SELL
$50.3 - $64.39 $21,377 - $27,365
-425 Reduced 2.96%
13,945 $0
Q3 2017

Nov 09, 2017

SELL
$45.56 - $59.57 $74,035 - $96,801
-1,625 Reduced 10.16%
14,370 $729,000
Q2 2017

Aug 14, 2017

BUY
N/A
15,995
15,995 $814,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Reynders Mc Veigh Capital Management, LLC Portfolio

Follow Reynders Mc Veigh Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.